iRadimed Valuation Multiples

iRadimed Overview

About iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Founded

1992

HQ

Employees

160

Website

iradimed.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $86M

EBITDA: $28M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

iRadimed Financials

iRadimed reported last 12-month revenue of $86M and EBITDA of $28M.

In the same LTM period, iRadimed generated $66M in gross profit, $28M in EBITDA, and $23M in net income.

iRadimed P&L

In the most recent fiscal year, iRadimed reported revenue of $84M and EBITDA of $27M.

iRadimed expects next 12-month revenue of XXX and NTM EBITDA of XXX

iRadimed Stock Performance

iRadimed has current market cap of $1B, and enterprise value of $1B.

iRadimed's stock price is $93.42.

iRadimed Valuation Multiples

iRadimed trades at 13.2x EV/Revenue multiple, and 40.8x EV/EBITDA.

iRadimed Financial Valuation Multiples

As of April 20, 2026, iRadimed has market cap of $1B and EV of $1B.

Equity research analysts estimate iRadimed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

iRadimed has a P/E ratio of 51.6x.

iRadimed Margins & Growth Rates

iRadimed's revenue in the last 12 month grew by 11%.

iRadimed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

iRadimed's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

iRadimed's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

iRadimed Public Comps

See public comps and valuation multiples for other Medical Devices comps.

iRadimed M&A Activity

iRadimed acquired XXX companies to date.

Last acquisition by iRadimed was on XXXXXXXX, XXXXX. iRadimed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

iRadimed Investment Activity

iRadimed invested in XXX companies to date.

iRadimed made its latest investment on XXXXXXXX, XXXXX. iRadimed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).